Search research articles
Contact Us
Filters
Showing results (1-10 of 16) with videos related to
Page
of 2
Sort By:
Current Opinion in Hematology
|
April 17, 2012
Shp2 function in hematopoietic stem cell biology and leukemogenesis
Sarah C Nabinger, Rebecca J Chan
Scientific Reports
|
November 3, 2019
The Role and Therapeutic Potential of miRNAs in Colorectal Liver Metastasis
Smiti S Sahu, Shatovisha Dey, Sarah C Nabinger, et al.
Oncotarget
|
November 21, 2017
Necdin modulates leukemia-initiating cell quiescence and chemotherapy response
Chonghua Yao, Michihiro Kobayashi, Sisi Chen, et al.
Cancer Research
|
February 3, 2011
The adaptor protein AMOT promotes the proliferation of mammary epithelial cells via the prolonged activation of the extracellular signal-regulated kinases
William P Ranahan, Zhang Han, Whitney Smith-Kinnaman, et al.
Journal of Surgical Oncology
|
August 5, 2018
Lower expression of tumor microRNA-26a is associated with higher recurrence in patients with hepatocellular carcinoma undergoing surgical treatment
Keaton R Jones, Sarah C Nabinger, Sangbin Lee, et al.
The Journal of Biological Chemistry
|
December 25, 2014
Protein-tyrosine phosphatase Shp2 positively regulates macrophage oxidative burst
Xing Jun Li, Charles B Goodwin, Sarah C Nabinger, et al.
Scientific Reports
|
June 23, 2015
Pathophysiological role of microRNA-29 in pancreatic cancer stroma
Jason J Kwon, Sarah C Nabinger, Zachary Vega, et al.
Journal of Medicinal Chemistry
|
February 23, 2010
Salicylic acid based small molecule inhibitor for the oncogenic Src homology-2 domain containing protein tyrosine phosphatase-2 (SHP2)
Xian Zhang, Yantao He, Sijiu Liu, et al.
Molecular and Cellular Biology
|
June 17, 2009
Increased c-Jun expression and reduced GATA2 expression promote aberrant monocytic differentiation induced by activating PTPN11 mutants
Zhenyun Yang, Takako Kondo, Cara S Voorhorst, et al.
Leukemia Research
|
March 23, 2011
Thrice weekly azacitidine does not improve hematological responses in lower-risk myelodysplastic syndromes: a study of the Hoosier Oncology Group
Hamid Sayar, Rebecca J Chan, Christie M Orschell, et al.
Page
of 2
Search research articles
Search
Showing results (1-10 of 16) with videos related to
Sort By:
Page
of 2
Current Opinion in Hematology
|
April 17, 2012
Shp2 function in hematopoietic stem cell biology and leukemogenesis
Sarah C Nabinger, Rebecca J Chan
Scientific Reports
|
November 3, 2019
The Role and Therapeutic Potential of miRNAs in Colorectal Liver Metastasis
Smiti S Sahu, Shatovisha Dey, Sarah C Nabinger, et al.
Oncotarget
|
November 21, 2017
Necdin modulates leukemia-initiating cell quiescence and chemotherapy response
Chonghua Yao, Michihiro Kobayashi, Sisi Chen, et al.
Cancer Research
|
February 3, 2011
The adaptor protein AMOT promotes the proliferation of mammary epithelial cells via the prolonged activation of the extracellular signal-regulated kinases
William P Ranahan, Zhang Han, Whitney Smith-Kinnaman, et al.
Journal of Surgical Oncology
|
August 5, 2018
Lower expression of tumor microRNA-26a is associated with higher recurrence in patients with hepatocellular carcinoma undergoing surgical treatment
Keaton R Jones, Sarah C Nabinger, Sangbin Lee, et al.
The Journal of Biological Chemistry
|
December 25, 2014
Protein-tyrosine phosphatase Shp2 positively regulates macrophage oxidative burst
Xing Jun Li, Charles B Goodwin, Sarah C Nabinger, et al.
Scientific Reports
|
June 23, 2015
Pathophysiological role of microRNA-29 in pancreatic cancer stroma
Jason J Kwon, Sarah C Nabinger, Zachary Vega, et al.
Journal of Medicinal Chemistry
|
February 23, 2010
Salicylic acid based small molecule inhibitor for the oncogenic Src homology-2 domain containing protein tyrosine phosphatase-2 (SHP2)
Xian Zhang, Yantao He, Sijiu Liu, et al.
Molecular and Cellular Biology
|
June 17, 2009
Increased c-Jun expression and reduced GATA2 expression promote aberrant monocytic differentiation induced by activating PTPN11 mutants
Zhenyun Yang, Takako Kondo, Cara S Voorhorst, et al.
Leukemia Research
|
March 23, 2011
Thrice weekly azacitidine does not improve hematological responses in lower-risk myelodysplastic syndromes: a study of the Hoosier Oncology Group
Hamid Sayar, Rebecca J Chan, Christie M Orschell, et al.
Page
of 2